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lacebo-Controlled Trial of Percutaneous
aser Myocardial Revascularization to Improve Angina
ymptoms in Patients With Severe Coronary Disease
artin B. Leon, MD, Ran Kornowski, MD, William E. Downey, MD, Giora Weisz, MD,
onald S. Baim, MD, Robert O. Bonow, MD, Robert C. Hendel, MD, David J. Cohen, MD, MSC,
rnest Gervino, DSC, Roger Laham, MD, Nicholas J. Lembo, MD, Jeffrey W. Moses, MD,
ichard E. Kuntz, MD, MSC
ew York, New York
OBJECTIVES This study was a randomized, patient- and evaluator-blinded, placebo-controlled trial in
patients treated using percutaneous myocardial laser revascularization.
BACKGROUND Previous studies using similar therapies have been confounded by placebo bias.
METHODS A total of 298 patients with severe angina were randomly assigned to receive low-dose or
high-dose myocardial laser channels or no laser channels, blinded as a sham procedure. The
primary end point was the change in exercise duration from baseline examination to six months.
RESULTS The incidence of 30-day death, stroke, myocardial infarction, coronary revascularization, or
left ventricular perforation occurred in two patients in the placebo, eight patients in the
low-dose, and four patients in the high-dose groups (p 0.12); 30-day myocardial infarction
incidence was higher in patients receiving either low-dose or high-dose laser (nine patients)
compared with placebo (no patients, p  0.03). At six months, there were no differences in
the change in exercise duration between those receiving a sham (28.0 s, n  100), low-dose
laser (33.2 s, n  98), or high-dose laser (28.0 s, n  98, p  0.94) procedure. There were
also no differences in the proportion of patients improving to better than Canadian
Cardiovascular Society class III angina symptoms at six months. The follow-up visual
summed stress single-photon-emission computed tomography scores were not significantly
different from baseline in any group and were no different between groups. The modest
improvement in angina symptoms assessed by the Seattle Angina Questionnaire also was not
statistically different among the arms.
CONCLUSIONS Treatment with percutaneous myocardial laser revascularization provides no benefit beyond
that of a similar sham procedure in patients blinded to their treatment status. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.06.079Cardiol 2005;46:1812–9) © 2005 by the American College of Cardiology Foundation
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sore than 100,000 patients each year have refractory or
nd-stage angina not amenable to percutaneous coronary
ntervention or coronary artery bypass graft surgery in the
.S. alone (1).
Surgical transmyocardial laser revascularization was devel-
ped to address this population of “no option” patients.
revious clinical trials have repeatedly shown improved angina
nd have also shown improved exercise tolerance in patients
reated with surgical transmyocardial laser revascularization
2–19). A catheter-based laser revascularization approach was
eveloped to provide equal clinical efficacy without the need for
thoracotomy or general anesthesia, thereby reducing proce-
ural complications and perhaps costs.
The Biosense direct myocardial revascularization (DMR)
olmium: yttrium-aluminum-garnet (Ho:YAG) laser system
Biosense-Webster, Diamond Bar, California) uses a magnet-
From the Cardiovascular Research Foundation, Center for Interventional Vascular
herapy, Columbia University Medical Center, New York, New York.o
Manuscript received January 5, 2005; revised manuscript received June 23, 2005,
ccepted June 27, 2005.ased catheter tip location system to allow the precise place-
ent of intra-myocardial laser channels (20–22). A phase I
tudy of 77 patients treated with this system showed favorable
esults at six months, with a significant improvement in both
ngina symptoms and exercise duration (23).
The possibility that placebo effects could be responsible
or the positive results of the previous unblinded surgical
nd percutaneous laser revascularization trials has been
aised. Therefore, the present study was designed to evaluate
he safety and efficacy of Biosense DMR using a patient-
linded and evaluator-blinded randomized trial design.
ETHODS
tudy design. This was a phase II, multicenter, random-
zed study, with prospective comparison of two treatment
roups (low-dose and high-dose) and a control group with
linded patient and end point evaluation. No crossover was
llowed, and all patients received the intended therapy. The
tudy was conducted at 14 U.S. centers with experience in
btaining Biosense LV electromechanical maps (see Appen-
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November 15, 2005:1812–9 Percutaneous Laser Myocardial Revascularizationix). The trial was approved for an investigational device
xemption by the U.S. Food and Drug Administration, and
ll sites received approval from their local institutional
eview boards. Written informed consent was obtained from
ll patients. Patient enrollment was initiated in October
998 and was completed in October 1999.
atient eligibility criteria. Patients were eligible for inclu-
ion in the study if they had a history of coronary artery
isease with refractory angina (Canadian Cardiovascular
ociety [CCS] class III or IV), despite optimal medical
herapy (including beta-adrenergic blockers, calcium antag-
nists, and nitrates). All patients were considered unaccept-
ble candidates for percutaneous revascularization therapies
r surgical revascularization procedures. All patients were
ble to complete a minimum of 2 min but not more than 12
in of a Beth Israel Modified Bruce Protocol exercise test,
nd had reversible ischemia during dual isotope perfusion
maging studies.
The principal exclusion criteria from the study included
evere left ventricular dysfunction (ejection fraction 30%,
ssessed by echocardiography), recent myocardial infarction
within 30 days of treatment), Braunwald class IIIb unstable
ngina, chronic atrial fibrillation, prosthetic valve or signif-
cant aortic valve pathology, myocardial wall thickness 9
m (by transthoracic echocardiography), left ventricular
hrombus, and major life-threatening comorbidity.
tudy end points. The pre-specified primary end point was
hange in exercise treadmill duration from baseline to six
onths. Pre-specified secondary end points included: 1)
ajor adverse cardiac events (MACE) at 30 days (the
omposite of cardiac death, acute Q-wave and non–Q-wave
yocardial infarction [MI], revascularization procedures for
rocedure-related complications or coronary ischemia, left
entricular [LV] perforation, and stroke); 2) the incidence
f MACE at 6 and 12 months; 3) the change in CCS
ngina classification score from baseline to 6 and 12 months;
) the change in health status and anginal symptoms using
semi-quantitative instrument incorporating the Medical
utcome Study, General Health Survey (SF-12), and
eattle Anginal Questionnaire from baseline to 6 and 12
onths; 5) the change in global and regional radionuclide
erfusion scores at rest, peak stress, and redistribution using
emi-quantitative and quantitative methods from baseline to
Abbreviations and Acronyms
CCS  Canadian Cardiovascular Society
DMR  direct myocardial revascularization
Ho:YAG  holmium: yttrium-aluminum-garnet
LV  left ventricle/ventricular
MACE  major adverse cardiac events
MI  myocardial infarction
SPECT  single-photon emission computed
tomography
TMR  transmyocardial laser revascularizationmonths; and 6) changes in all exercise test parameters (ncluding duration, time to angina, and time to ST-segment
hanges from baseline to 6 and 12 months.
yocardial perfusion imaging. At baseline and at six
onths after the randomized DMR procedure, all patients
nderwent dual-isotope single-photon-emission computed
omography (SPECT) myocardial perfusion imaging with
mCi 201Tl at rest and 25 mCi 99mTc-sestamibi for
denosine stress imaging according to previously published
ethodology (24). Sestamibi was administered at three
inutes during the six-minute adenosine infusion (140
g·kg1·min1). Stress imaging was performed beginning
0 min after 99mTc-sestamibi injection. These data were
ubmitted to the central core laboratory for blinded uniform
rocessing, interpretation, and comparative analysis. A 20-
egment semiquantitative visual analysis was used as well as
n automated quantitative analysis. The summed scores of
est, rest redistribution, and stress images were determined
t six-month follow-up and compared with baseline values.
V mapping and the randomized DMR procedure. All
atients were heavily sedated, had blindfolds, and had
arphones with music to minimize the potential for inad-
ertent identification of the treatment modality. The LV
lectromechanical mapping was performed according to
reviously described guidelines (20–23). Heparin was ad-
inistered (70 U/kg) and supplemented as needed to
aintain an activated clotting time of 200 to 250 s. The
cquisition of an acceptable LV map (70 to 100 points)
sually required approximately 30 min. Treatment zones,
enerally subtending the anatomic distribution of one of the
hree major epicardial coronary arteries (left anterior de-
cending, left circumflex, and/or right coronary artery), were
re-specified using the combination of a recent coronary
ngiogram, the SPECT imaging results, and the diagnostic
V electromechanical map (23). Areas of previous infarc-
ion (Q waves on the electrocardiogram, myocardial wall
hickness 9 mm, or voltage amplitudes of 5 mV) were
arefully excluded as treatment zones. The DMR was
erformed in one or two designated treatment zones in each
atient.
After completing the LV mapping procedure and decid-
ng on the potential DMR treatment zones, the patients
ere randomized to placebo (mock procedure, 102 pa-
ients), low-dose (98 patients), or high-dose (98 patients)
MR treatment. If the patient was randomized to placebo,
he laser (already in the room) was turned on but no further
rocedure was performed. If the patient was randomized to
eceive the Biosense DMR treatment, a laser catheter was
ntroduced and advanced to the LV. The laser source was a
ulsed Ho:YAG laser (Sharplan 2040; Ho:YAG Laser
ystems, Lumenis, New York, New York). Laser channels
ere created using a tip-deflecting mapping and Ho:YAG
aser catheter integrated with a 300 m fiber (LaserStar;
iosense-Webster). A single laser pulse (2 J/pulse) was fired
erpendicular to the endocardial surface with the catheter
ip icon used to verify the location. Either 10 to 15
low-dose) or 20 to 25 (high-dose) laser pulses were fired
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Percutaneous Laser Myocardial Revascularization November 15, 2005:1812–9ithin the treatment zone with 5- to 10-mm spacing
etween each laser pulse. At the conclusion of the laser
MR procedure (usually lasting an additional 30 min), all
atients were monitored (electrocardiogram and arterial
ressures) in the catheterization laboratory for 15 min.
atient blinding to the procedural randomization code was
reserved by continuous heavy sedation, sensory isolation
blindfold and music), and lack of patient familiarity with
rocedural details and duration (i.e., patients could not
ifferentiate the LV mapping procedure alone from the LV
apping plus DMR procedure).
At the end of the procedure, blood samples for creatine
inase-MB were acquired from all patients every 8 h for
4 h after the procedure. In addition, 12-lead electrocar-
iograms were obtained at the end of the procedure and the
orning after the procedure.
ollow-up assessments and data collection. All follow-
p assessments and data were collected by study coordina-
ors and research assistants blinded to treatment identity.
ajor adverse cardiovascular events were recorded in-
ospital, at 30 days, and at 3, 6, and 12 months. Exercise
ests and CCS angina class were obtained at 3, 6, and 12
onths (core laboratory: Beth Israel-Deaconess Hospital,
oston, Massachusetts). Dual-isotope adenosine stress ra-
ioisotope perfusion imaging was repeated at six months
core laboratory: Northwestern University, Chicago, Illi-
ois). Standardized quality of life assessments were obtained
y independent research monitors at 6 and 12 months (core
aboratory: Cardiovascular Data Analysis Center, Boston,
assachusetts).
Case-report forms were completed at each site, moni-
ored by independent study monitors, and submitted to the
ata-coordinating center (Cardiovascular Data Analysis
enter, Harvard Clinical Research Institute, Boston, Mas-
achusetts). All events were classified by an independent
linical events committee that was unaware of each patient’s
reatment assignment. Angiograms obtained before the
rocedure were submitted to an angiographic core labora-
ory (Cardiovascular Research Foundation, New York, New
ork) for independent assessment.
tatistical analysis. The sample size was based on 80%
ower to detect a 15% relative increase in exercise duration
rom an expected baseline of 7.4 2 min (at  0.05). The
5% relative increase was chosen because it represents a
ifference of approximately 1 min, which was thought to be
he minimal clinically relevant difference in exercise
uration.
Continuous variables including exercise duration, change
n exercise duration, Seattle Angina Questionnaire scores,
nd SPECT myocardial perfusion scores were compared by
nalysis of variance under the null hypothesis of no differ-
nce among the arms, with a post-test procedure for
airwise comparisons to be performed whenever the analysis
f variance false-positive rate was 5%. The binary end
oints of MACE and2 CCS class change were compared
sing exact methods. A secondary analysis of the primary ind point was undertaken using multivariable linear regres-
ion to control for differences in selected baseline covariates.
hese selected covariates were chosen if they differed
etween groups at a significance level of p 0.20 (prior MI,
ercutaneous coronary intervention, or coronary artery by-
ass graft) or they were thought to be potentially important
linical indicators of the change in exercise performance
baseline exercise treadmill test duration, ejection fraction,
iabetes, and symptom presentation).
All statistical tests were two-sided, with a p value  0.05
onsidered significant. Analyses were performed with SAS
oftware (version 8.2, SAS Institute Inc., Cary, North
arolina).
ESULTS
wo hundred ninety-eight patients were enrolled at 14
nvestigational sites; 98 were assigned to the low-dose
MR group, 98 patients to the high-dose DMR group, and
02 patients to the placebo group.
atient demographics. The mean patient age was 62.9 
0.1 years, 77% were male, and hypertension, diabetes
ellitus, and hyperlipidemia were present in 73.5%, 43.9%,
nd 83.2% of patients, respectively. Prior myocardial infarc-
ion and prior coronary artery bypass graft operation were
eported in 67.0% and 88.3% of patients, respectively. The
ean left ventricular ejection fraction was 49.3  12.0%.
ll baseline patient demographics were similar in the three
atient groups.
rocedural details. Full electromechanical maps were ob-
ained without complications in all but one patient, in
hom the procedure was aborted after transient right side
eakness and aphasia developed. The overall number of
apping points was 69  19 (range, 1 to 136), and the LV
apping time before DMR was 33  14 min (range, 6 to
5 min). In the treatment phase of the study, the low-dose
atients received an average of 21  8 laser channels in an
verage of 1.4  0.5 treatment zones. The high-dose
atients received an average of 34  11 laser channels in an
verage of 1.5  0.5 treatment zones.
n-hospital and 30-day clinical events. In-hospital
rocedure-related adverse events in the combined active
reatment groups (low-dose or high-dose) included death in
ne patient (0.5%), Q-wave or non–Q-wave myocardial
nfarctions in seven patients (3.6%), strokes in two patients
1.0%), and LV perforation in one patient (0.5%). In the
lacebo patients, other than vascular complications in two
atients (2.0%), there were no other adverse in-hospital
linical events. The primary safety end point (30-day
ACE) occurred in 4.1% of the low-dose patients, in 8.2%
f the high-dose patients, and in 2.0% of the placebo
atients (p  0.117). Myocardial infarction (Q-wave or
on–Q-wave) occurred in nine of the DMR-treated patients
nd in none of the placebo patients (p 0.026 at 30 days). The
n-hospital and 30-day adverse events are detailed in Table 1.
F
i
f
l
1
7
p
h
s
m
I
r
a
C
w
a
i
t
t
m
cular a
1815JACC Vol. 46, No. 10, 2005 Leon et al.
November 15, 2005:1812–9 Percutaneous Laser Myocardial Revascularizationollow-up clinical events. Six and 12 months after the
ndex procedure, there were no statistically significant dif-
erences in cumulative death, acute MI, or repeat revascu-
arization among the three treatment groups (Table 2, Fig.
). At 12 months, death or acute MI occurred in 9.2%,
.2%, and 7.8% of patients in the high-dose, low-dose, and
lacebo treatment groups, respectively. Of 13 deaths (4
igh-dose, 4 low-dose, 5 placebo), 9 were cardiac with
imilar distribution between groups. Death occurred at a
ean of 195 days (range, 5 to 360 days) after the procedure.
Table 1. Adverse Clinical Events: In-Hospital
Events
High Dose
n  98 (%)
Overall primary safety end point
In hospital 4 (4.1)
At 30 days 4 (4.1)
Death
In hospital 1 (1.0)
At 30 days 1 (1.0)
Acute MI
Q-wave and non–Q-wave MI
In hospital 3 (3.1)
At 30 days 3 (3.1)
Q-wave MI
In hospital 0 (0)
At 30 days 0 (0)
Non–Q-wave MI
In hospital 3 (3.1)
At 30 days 3 (3.1)
CVA
In hospital 0 (0)
At 30 days 0 (0)
LV perforation
In hospital 1 (1)
At 30 days 1 (1)
Revascularizion (PCI or CABG)
In hospital 1 (1)
At 30 days 1 (1)
CABG coronary artery bypass grafting; CVA cerebrovas
 percutaneous coronary intervention.
Table 2. Adverse Clinical Events at 6 and 12 M
Events
High Do
n  98 (
Overall major adverse cardiac events
At 6 months 10 (10.2
At 12 months 19 (19.4
Death
At 6 months 2 (2.0)
At 12 months 4 (4.1)
Acute MI
Q-wave MI
At 6 months 0 (0)
At 12 months 0 (0)
Non–Q-wave MI
At 6 months 8 (8.2)
At 12 months 8 (8.2)
Revascularization (PCI or CABG)
At 6 months 3 (3.1)
At 12 months 10 (10.2Abbreviations as in Table 1.mportantly, there were no significant differences in repeat
evascularization events among the three treatment groups
t 6 or 12 months after the index procedure.
hanges in exercise parameters. The primary end point
as similar for the three groups, and importantly, there was
similar significant improvement in exercise duration dur-
ng the 6-month follow-up for both the active and placebo
reatment patients. This significant improvement was main-
ained for all treatment groups during the 12-month assess-
ents (Table 3, Fig. 2). Other exercise parameters evaluated
at 30 Days
Low Dose
n  98 (%)
Placebo
n  102 (%) p Value
6 (6.1) 0 (0) 0.026
8 (8.2) 2 (2.0) 0.117
0 (0) 0 (0) 0.658
1 (1.0) 2 (2.0) 0.548
4 (4.1) 0 (0) 0.103
6 (6.1) 0 (0) 0.026
2 (2) 0 (0) 0.215
2 (2) 0 (0) 0.215
2 (2.0) 0 (0) 0.208
4 (4.1) 0 (0) 0.103
2 (2) 0 (0) 0.215
2 (2) 0 (0) 0.215
0 (0) 0 (0) 0.658
0 (0) 0 (0) 0.658
0 (0) 0 (0) 0.658
0 (0) 2 (2.0) 0.776
ttack; LV left ventricle; MI myocardial infarction; PCI
hs
Low Dose
n  98 (%)
Placebo
n  102 (%) p Value
9 (9.2) 9 (8.8) 0.968
13 (13.3) 11 (10.8) 0.223
1 (1.0) 3 (2.9) 0.874
4 (4.1) 5 (4.9) 1.0
2 (2.0) 1 (1.0) 0.544
2 (2.0) 1 (1.0) 0.544
4 (4.1) 2 (2.0) 0.117
5 (5.1) 2 (2.0) 0.129
4 (4.1) 6 (5.9) 0.684
6 (6.1) 7 (6.9) 0.585andont
se
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Percutaneous Laser Myocardial Revascularization November 15, 2005:1812–9time to angina and time to ST-segment depression) im-
roved significantly from baseline to 6 months and from
aseline to 12 months, but the improvements were similar,
ithout any consistent differences among the three groups
t 6 and 12 months (Table 3).
hanges in angina severity. Significant improvement in
CS angina class was noted for all treatment groups at 6
onths (to CCS class 2.0  1.2, 1.9  1.3, and 2.2  1.2,
n high-dose, low-dose, and placebo groups, respectively,
 0.413), which was maintained during the 12-month
ssessment. Improvement of at least two CCS angina classes
as noted in 41%, 48%, and 41% of the high-dose,
ow-dose, and placebo groups, respectively, at six months.
igure 3 shows that the proportions of patients with CCS
II to IV angina at 6 and 12 months were similar in all three
roups.
uality-of-life assessments. Analysis of quality-of-life as-
essment instruments indicated significant improvements at
and 12 months for all of the treatment groups, but no
ifferences among the three groups (Table 4). Specifically,
ngina frequency and stability, physical functioning, treat-
ent satisfaction, disease perception, and current overall
ealth were all improved, but without indications of a DMR
reatment effect.
igure 1. Freedom from major adverse cardiac events (MACE) from the
ndex procedure to 12 months. Comparisons between groups at 12 months
ere not statistically significant.
able 3. Changes in Treadmill Exercise Parameters
High Dos
(n  98)
xercise duration (s)
Baseline 393.0  154.2
6-month follow-up* 421.4  156.6 (0
12-month follow-up† 431.2  175.4 (0
ime to onset of 1-mm ST-segment depression (s)
Baseline 342.7  147.0
6-month follow-up* 388.5  154.3 (0
12-month follow-up† 395.9  166.9 (0
ime to onset of angina (s)
Baseline 285.3  144.7
6-month follow-up* 337.2  169.4 (0
12-month follow-up† 368.0  190.9 (lus-minus values are mean  standard deviation. *Numbers in parentheses represent p val
alue of the comparison of 12 months to baseline.adioisotope imaging studies. During the follow-up ra-
ioisotope imaging studies, quantitative scores of the mean
schemic areas per patient, at rest and during stress, showed
o significant changes suggesting an anti-ischemic effect,
nd were similar among the three treatment groups (at rest,
.5  5.2, 8.7  7.9, 7.3  6.2, p  0.390; during stress,
7.7  8, 19.3  9.5, 17.3  7.6, p  0.345 for high-dose,
ow-dose, and placebo patients, respectively).
ISCUSSION
he present study. This study was the first randomized,
lacebo-controlled, blinded assessment of DMR in patients
ith refractory angina. A comparison of placebo (sham)
ith two treatment groups (differing in the numbers of laser
hannels) using the Biosense DMR system showed no
ifferences in exercise duration (primary end point), exercise
ime to the onset of chest pain, and exercise time to the
ppearance of ST-segment changes at 6 and 12 months.
here were also no differences among the treatment groups
n the improvement in angina frequency and in all other
uality-of-life parameters. Moreover, there was an increased
ate of adverse clinical events associated with laser treatment
t 30 days. There were also no changes in myocardial
erfusion, as manifested by rest and stress SPECT nuclear
maging studies done at 6 months.
Low Dose
(n  98)
Placebo
(n  102) p Value
366.0  146.8 358.6  146.5 0.240
432.2  150.8 (0.005) 396.6  175.1 (0.033) 0.348
425.7  153.7 (0.046) 395.3  177.9 (0.057) 0.334
350.0  143.4 330.1  149.7 0.606
410.5  156.5 (0.059) 369.2  178.6 (0.059‡) 0.273
406.8  154.7 (0.139) 370.8  175.0 (0.072) 0.361
269.7  134.8 272.7  143.8 0.718
335.4  156.4 (0.003) 312.5  161.4 (0.085) 0.548
1) 363.4  140.3 (0.001) 320.8  183.4 (0.049) 0.152
igure 2. Exercise duration(s) at baseline, at 6 months, and at 12 months
f follow-up and the change in exercise duration between baseline and 6
onths. The change in exercise duration was maintained at 12 months. All
omparisons between groups were not statistically significant.e
.024)
.003)
.005)
.004)
.003)
0.00ue of the comparison of 6 months to baseline. †Numbers in parentheses represent p
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November 15, 2005:1812–9 Percutaneous Laser Myocardial Revascularizationrevious laser transmyocardial laser revascularization
TMR) clinical studies. The negative results from this
linded randomized trial are in striking contrast to an
xtensive literature purporting to show the clinical benefits
f either surgical or catheter-based laser myocardial revas-
ularization procedures in patients with end-stage symp-
omatic coronary ischemia. Using surgical TMR modalities
o treat “no option” patients, there have been 11 observa-
ional studies with at least one-year clinical follow-up
2–12) and six non-blinded randomized studies (13–18)
igure 3. Canadian Cardiovascular Society angina class III or IV at
aseline and 6- and 12-month follow-up. All comparisons between groups
ere not statistically significant.
Table 4. Quality-of-Life Assessments at Baseli
Scale
High Dose
(n  98)
PCS-12†
Baseline 26.7  6.6
6 months 33.3  10.0
12 months 32.8  10.2
MCS-12‡
Baseline 45.2  11.2
6 months 47.7  11.2
12 months 47.8  11.1
Physical functioning§
Baseline 34.0  14.9
6 months 54.3  24.0
12 months 49.2  21.5
Anginal stability§
Baseline 33.2  23.3
6 months 63.9  29.7
12 months 58.3  28.2
Anginal frequency§
Baseline 33.8  23.0
6 months 56.7  28.7
12 months 52.7  28.4
Treatment satisfaction§
Baseline 66.7  20.2
6 months 72.5  20.2
12 months 70.1  20.7
Disease perception§
Baseline 29.1  16.5
6 months 53.0  26.0
12 months 49.7  25.9
Overall health
Baseline 47.5  20.2
6 months 59.4  24.6
12 months 56.4  22.1
Values are mean  standard deviation. *p Value determined
score (range, 24.0 to 56.6, higher is better). ‡MCS-12, mental com
§Score range, 0 to 100, higher is better.ersus best medical therapy. The most consistent beneficial
nding was a significant improvement in CCS angina class,
hich seemed to peak by six months, but sustained angina
enefit at three and five years has also been reported (8,25).
xercise tests, performed in approximately half the studies,
lso showed improved exercise duration, but myocardial
erfusion assessments were unsuccessful in showing im-
roved regional or global myocardial perfusion after TMR
herapy.
There have now been five randomized clinical trials
including the present study), involving 1,072 patients,
xamining the safety and efficacy of percutaneous laser
yocardial revascularization (26–29). The first two studies
26,27) were non-blinded versus best medical therapy and
howed improved angina symptoms and exercise duration.
mportantly, the percutaneous TMR procedures were not
ithout associated complications; in the present study, there
ere increased acute adverse events in the laser-treated
atients, and in another study (27), there were five episodes
3% of the TMR patients) of myocardial perforation result-
ng in cardiac tamponade. In addition to the present study,
here are two other percutaneous TMR studies that have
-Month, and 12-Month Follow-Up
ow Dose
n  98)
Placebo
(n  102) p Value*
.6  7.1 26.0  6.1 0.763
.8  10.0 33.8  9.8 0.826
.5  10.5 32.4  9.6 0.800
.8  11.4 43.7  10.2 0.345
.6  11.7 47.2  12.5 0.951
.6  11.7 46.3  11.7 0.497
.5  21.2 37.2  17.9 0.446
.7  23.3 54.0  25.6 0.745
.7  25.3 50.0  22.8 0.296
.9  27.0 31.5  24.7 0.500
.1  30.3 62.2  31.3 0.908
.2  33.3 58.1  33.6 0.978
.6  24.6 35.5  23.7 0.882
.1  29.7 60.1  29.3 0.727
.5  29.2 53.8  31.8 0.326
.8  19.8 65.0  19.3 0.622
.1  21.8 72.6  20.0 0.984
.6  18.8 67.6  24.0 0.210
.9  16.1 29.4  18.5 0.323
.8  26.0 55.6  25.5 0.713
.8  27.7 50.9  26.6 0.218
.3  20.9 45.9  18.6 0.768
.1  20.6 63.4  21.2 0.342
.4  24.1 59.5  23.0 0.514
nalysis of variance. †PCS-12, physical component summaryne, 6
L
(
26
32
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42
47
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51
54
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72
73
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using a
ponent summary score (range, 19.1 to 60.8, higher is better).
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Percutaneous Laser Myocardial Revascularization November 15, 2005:1812–9sed a blinded sham control arm to eliminate the influence
f placebo effects on outcomes (28,29). In a study involving
41 patients with failed recanalization of chronic total
cclusions (28), no differences were observed in follow-up
ngina symptoms and in exercise test parameters between
he two groups. In a smaller study (82 patients) (29) using
true placebo sham procedure, there was an improvement
n CCS angina scores associated with laser treatment.
owever, exercise test results and anti-anginal medication
sage were similar between the two groups at 12 months.
tudy result comparisons. Clearly, there are many dis-
repant findings when comparing blinded and non-blinded
ercutaneous TMR trials, and more generally, when com-
aring the ambiguous results of the percutaneous random-
zed trials with the more consistent positive outcomes from
he surgical randomized (but non-blinded) TMR studies.
rguments forwarded to explain the differences between
ercutaneous and surgical TMR randomized clinical trials
ave focused on procedural details, such as differences in
aser channel density (30,31) and laser channel depth
greater with surgical TMR) and more precise localization
f the laser channels during surgery.
Rather than imposing procedural issues as the explana-
ion for the disparate findings, we submit that a fundamen-
al difference in clinical trial methodology is the likely
ausative factor. The patients studied in these trials had
evere angina symptoms and had exhausted all forms of
onventional therapy. They were highly motivated and
esperate for a novel therapy to provide symptom relief, and
hey had high expectations for clinical benefit. It is recog-
ized that the greater the subject’s stress, the greater the
lacebo effect (32,33), particularly when pain is the subjec-
ive end point (34), and it has been argued that devices
nd procedures have a larger placebo effect than do pills
35). There is an extensive literature on the dangers of
on–placebo-controlled anti-anginal studies (36), and one
an expect a 30% to 80% improvement in angina symptoms
nd a 90-s to 120-s improvement in exercise duration after
lacebo treatment alone. There are also previous examples
f novel highly touted surgical therapies for angina relief,
ncluding internal mammary artery ligation in the 1950s,
hat were cast aside after rigorous placebo-controlled
linded studies were performed (37,38). For these very
easons, the present placebo-controlled blinded clinical trial
as designed to eliminate both patient and investigator bias
n the interpretation of outcome end points. There was a
ronounced placebo effect in the present study resulting in
30% improvement in exercise duration and angina symp-
oms that was sustained for 12 months and was identical to
oth laser treatment arms.
echanisms of laser TMR. Another disturbing compo-
ent of the surgical and percutaneous TMR saga is confu-
ion surrounding the pathophysiologic mechanism(s) to
xplain the observed clinical benefits. It seems clear that
ersistent open transendocardial laser channels with direct
yocardial perfusion are rarely observed (39,40). Earlierheories of epicardial denervation to rationalize chest pain
elief have been similarly discounted (41). The final and
ost plausible theory, local angiogenesis caused by injury,
hrombosis, and inflammation, has been suggested in ex-
erimental histopathology studies (42,43) and by upregula-
ion of angiogenic growth factors (44,45). Nevertheless,
mproved regional myocardial perfusion associated with
ngiogenesis after laser TMR has been much more difficult
o show in animal models (46,47). This parallels the
onsistent negative findings when standard myocardial per-
usion imaging assessments are included in either surgical or
ercutaneous laser TMR studies.
tudy limitations. There are several limitations in the
resent study that should be considered: 1) Although we are
naware that catheter-based endocardial trauma has ever
een associated with angina relief, the diagnostic LV
apping procedure performed in all patients may have
nduced sufficient endocardial trauma in the placebo sham
atients to minimize the incremental effects of the laser
reatment. 2) There may be more optimal lasing parameters
channel size and depth, injury zone, and so on) than those
sed in this study, which can be explored in the future to
urther improve clinical outcomes. 3) This is a single clinical
tudy using a specific laser system, and the results, although
oncordant with one blinded percutaneous TMR study
28), are somewhat discordant with another blinded trial
29), indicating that additional large blinded studies with
ther laser TMR systems are warranted.
onclusions and clinical implications. In this blinded
andomized clinical trial, using the percutaneous Biosense
aser DMR system in so-called “no option” patients with
efractory angina, a substantial placebo effect was observed
uring sham therapy, and no incremental clinical benefits
ould be discerned after low-dose or high-dose laser treat-
ent. In fact, the laser therapy was associated with more
requent acute MI (usually non–Q-wave) during the first 30
ays. Based on these findings, we believe that all other
linical trials in this field should be viewed with caution and
kepticism, unless proper attention is taken to account for
lacebo effects of the experimental laser therapies.
eprint requests and correspondence: Dr. Martin B. Leon,
ardiovascular Research Foundation, Center for Interventional
ascular Therapy, Columbia University Medical Center, 161 Fort
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PPENDIX
or the additional institutions and investigators that partic-
pated in the DIRECT trial, please see the online version of
his article.
